New FDA Framework Spurs Personalized Gene Therapy for Rare Liver Disorders

Researchers develop customizable in vivo prime editing platform to treat urea cycle disorders and other genetic liver diseases.

Mar. 31, 2026 at 5:05pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft earth tones featuring sweeping geometric shapes, concentric circles, and precise botanical spirals, conceptually representing the complex genetic and molecular forces involved in rare liver disorders.A new FDA framework aims to accelerate the development of personalized gene therapies for rare, inherited liver disorders like urea cycle diseases.Philadelphia Today

Researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have reported results supporting a customizable in vivo prime editing platform designed to treat infantile-onset urea cycle disorders (UCDs), rare liver diseases that can cause dangerous ammonia buildup. The work was done with the FDA's new 'plausible mechanism' framework in mind, which aims to accelerate development of highly personalized genetic treatments for ultra-rare diseases.

Why it matters

The FDA's new framework opens the door for faster development of personalized therapies for rare genetic disorders, but academic teams will likely need industry partnerships to meet the rigorous standards required for approval. This research demonstrates how the plausible mechanism approach can be applied to create a flexible gene-editing solution for multiple UCD variants.

The details

The two-part prime editing system uses a lipid nanoparticle to deliver mRNA encoding the editor to the liver, plus a customized adeno-associated virus that supplies the short guide RNAs. In preclinical studies, this approach corrected 30-40% of the genetic variant copies in liver DNA - much higher than the 10% typically considered necessary for clinical benefit in UCDs. The researchers plan to discuss a single 'umbrella-of-umbrellas' phase I/II trial with the FDA that would allow patients across all seven UCD genes to enroll while receiving customized prime-editing therapies.

  • In February 2026, researchers celebrated the one-year anniversary of the world's first person receiving a personalized gene-editing therapy for a severe UCD.
  • That same week, the FDA announced its draft 'plausible mechanism' framework for faster development of highly personalized genetic treatments.

The players

Rebecca Ahrens-Nicklas

Director of CHOP's Gene Therapy for Inherited Metabolic Disorders Frontier Program.

Kiran Musunuru

Co-Director of the Orphan Disease Center, a partnership between CHOP and Penn Medicine.

Children's Hospital of Philadelphia (CHOP)

A non-profit, charitable organization and the nation's first pediatric hospital, known for its pioneering research and advanced patient care.

Penn Medicine

A health system and academic medical center in Philadelphia, partnering with CHOP on the Orphan Disease Center.

Broad Institute

A biomedical and genomic research center that collaborated on this research project.

Got photos? Submit your photos here. ›

What they’re saying

“This two‑part approach delivers robust, potentially therapeutic, correction in liver tissue and has the potential to be rapidly customized for individual patient genetic variants.”

— Rebecca Ahrens-Nicklas, Director of CHOP's Gene Therapy for Inherited Metabolic Disorders Frontier Program

“We view the FDA's draft plausible mechanism framework guidance as an opportunity to accelerate development and approval of individualized therapies for ultra‑rare genetic diseases.”

— Kiran Musunuru, Co-Director of the Orphan Disease Center

What’s next

The researchers recently had a meeting with the FDA to discuss a single 'umbrella‑of‑umbrellas' phase I/II trial that would allow patients across all seven UCD genes to enroll while receiving customized prime-editing therapies.

The takeaway

This research demonstrates how the FDA's new 'plausible mechanism' framework can be leveraged to accelerate the development of highly personalized gene therapies for rare, inherited liver disorders. However, academic teams will likely need strong industry partnerships to navigate the rigorous standards required for approval of these complex, individualized treatments.